TNBC Symposium

December 3, 2018 - San Antonio, TX
This event brought together 34 of the world’s top researchers to discuss key areas of progress and the challenges that they face in moving forward with better treatments for this disease. Topics included Precision Medicine, PARP inhibitors, Immunotherapy, and a fascinating review of “Oncological Anthropology,” the genetics of TNBC in African American patients as well as an analysis of the treatment related toxicities and outcomes in specifically related to race in TNBC.

Welcome
Hayley Dinerman, TNBC Foundation Executive Director

Precision Medicine for TNBC patients using genomic subtyping
Charles M. Perou, PhD

PARPi – Current status, future directions
Mark E. Robson, MD

Discussion
Facilitated by George W. Sledge, MD

Immunotherapy and monoclonal antibodies: role of immune therapy in TNBC and predictors of response
Giuseppe Curigliano, MD, PhD

Discussion
Facilitated by Eric P. Winer, MD

Oncologic Anthropology: Genetics of African ancestry and TNBC
Lisa Newman, MD, MPH

Cancer Disparities: Impact of Toxicities & Outcomes Specific to Race in TNBC
Bryan P. Schneider, MD

Discussion
Facilitated by Lisa A. Carey, MD

Closing Remarks
Eric P. Winer, MD

Sylvia Adams, MD           
NYU Langone Health

Sunil Badve, MBBS, MD, FRCPath             
Indiana University School of Medicine

Lisa A. Carey, MD            
University of North Carolina
Lineberger Comprehensive Cancer Center

Massimo Cristofanilli, MD            
Northwestern University

Giuseppe Curigliano, MD, PhD   
European Institute of Oncology

Rebecca Dent, MSc MD FRCP
National Cancer Center Singapore, Duke-NUS

Hayley Dinerman
TNBC Foundation Executive Director

Leisha Ann Emens, MD, PhD     
Johns Hopkins Medicine

Ricki Fairley
TNBC Foundation Board Chair

Elizabeth Frank             
Dana-Farber Cancer Institute

Ana Garrido-Castro, MD
Dana-Farber Cancer Institute

Steven Jay Isakoff, MD, PhD       
Massachusetts General Hospital

Steve Kandel     
Sage Patient Advocates

Ian E. Krop, MD, PhD     
Dana-Farber Cancer Institute

Sherene Loi, MD, PhD   
Peter MacCallum Cancer Centre
University of Melbourne

Elizabeth Mittendorf, MD, PhD 
Dana-Farber Cancer Institute

Stacy Moulder, MD        
MD Anderson Cancer Center

Lisa Newman, MD          
Weill Cornell Medicine

Ben Park, MD, PhD         
Vanderbuilt University Medical Center

Mark Pegram, MD          
Stanford University School of Medicine

Charles M. Perou, PhD  
University of North Carolina
Lineberger Comprehensive Cancer Center

Lajos Pusztai, MD, PhD  
Yale School of Medicine

Andrea Richardson, MD, PhD     
Johns Hopkins Medicine

Mark Robson, MD           
Memorial Sloan-Kettering Cancer Center

Hope Rugo, MD
UCSF, Helen Diller Family Comprehensive Cancer

Bryan Schneider, MD     
Indiana University School of Medicine

William Sikov , MD          
Brown University

George W. Sledge, Jr., MD           
Stanford University School of Medicine

Daniel G. Stover, MD 
Ohio State University Comprehensive Cancer Center

Melinda L. Telli, MD       
Stanford University School of Medicine

Tiffany Traina, MD          
Memorial Sloan-Kettering Cancer Center

Eric P. Winer, MD            
Dana-Farber Cancer Institute

Antonio C. Wolff, MD    
Johns Hopkins Medicine